Objective-To evaluate longitudinal changes in 6 inflammatory markers that predict cardiovascular disease events among smokers making a quit attempt and to characterize their cross-sectional associations between smoking and smoking heaviness. Approach and Results-In a longitudinal cohort study of contemporary smokers (n=1652), we evaluated (1) independent associations of smoking heaviness markers (exhaled carbon monoxide, cigarettes/d, pack-years) with inflammatory markers (C-reactive protein, D-dimer, fibrinogen, urinary F 2 isoprostane:creatinine [F 2 :Cr] ratio, white blood cell [WBC] count, myeloperoxidase) and (2) the effects of smoking cessation and continued smoking on these inflammatory markers after 1 year, among the 888 smokers who made an aided quit attempt as part of a randomized comparative effectiveness trial or standard care. There were strong, independent associations between smoking heaviness markers and the F 2 :Cr ratio, WBC, and myeloperoxidase (all P adj <0.001), but not high-sensitivity C-reactive protein, D-dimer, or fibrinogen. Participants were mean (SD) 49.6 years old (11.6), 54% women, 34% non-white, and smoked 16.8 cigarettes/d (8.5) for 27.3 pack-years (18.6). After 1 year, the 344 successful abstainers gained more weight (4.0 [6.0] versus 0.4 [5.7] pounds; P<0.001) and had larger increases in insulin resistance scores (P=0.02) than continuing smokers. Despite these increases, abstainers had significant decreases in F 2 :Cr ratio (P<0.001) and WBC counts (P<0.001). Changes in other markers were not related to quitting. Conclusions-Smoking heaviness is associated with increased F 2 :Cr ratio, myeloperoxidase, and WBC counts. Cessation improves the F 2 :Cr ratio and WBC counts independent of weight change, suggesting reduced inflammation related to less oxidant stress. 
I
n the United States, cigarette smoking contributes to nearly a half a million deaths annually with significant morbidity and mortality attributable to cardiovascular disease (CVD).
1,2 Indeed, smoking accounts for greater than one third of the population-attributable risk for myocardial infarction. 1 Smoking cessation is linked to lower CVD mortality and reductions in thrombotic events, most notably acute myocardial infarction. [3] [4] [5] [6] Atherosclerosis is a response to arterial injury, mediated by inflammation. [7] [8] [9] Clinical CVD events have been linked to elevated levels of inflammatory markers such as C-reactive protein (CRP), [10] [11] [12] D-dimer, fibrinogen, myeloperoxidase, white blood cell (WBC) count, [13] [14] [15] and urinary F 2 isoprostanes, a lipid peroxidation end product. 16 Tobacco-induced activation of inflammatory pathways, lipid oxidation, hypercoagulability, and vascular dysfunction is among the primary mechanisms by which cigarette smoking promotes CVD. 17, 18 Previous cross-sectional studies have demonstrated that active cigarette smokers have higher levels of inflammatory markers such as CRP, WBC count, fibrinogen, D-dimer, 10, 19, 20 and F 2 isoprostanes. 21, 22 However, no studies that we are aware of have investigated the longitudinal effects of smoking cessation and continued smoking on inflammatory markers associated with CVD risk. 20, 23 Furthermore, the observational studies published to date have had important limitations: some were small, they often did not adjust for confounders that affect inflammatory marker levels (ie, age, sex, adiposity, and insulin resistance), did not study newer inflammatory markers, and importantly, participants likely were not representative of contemporary smokers who tend to be more overweight than historical cohorts. 24 To address this critical gap in our understanding of smoking-associated arterial disease, we analyzed the crosssectional and longitudinal relationships between smoking burden, smoking cessation, and 6 inflammatory markers that predict CVD events (CRP, D-dimer, fibrinogen urinary F 2 isoprostane:creatinine [F 2 :Cr] ratio, myeloperoxidase, and WBC count) in a large cohort of contemporary smokers.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Subject Characteristics
Baseline subject characteristics are shown in Table 1 an aided quit attempt and completed year 1 assessments also are in Table 1 .
Baseline Associations of Smoking Heaviness Markers with Inflammatory Markers
Associations of the 6 inflammatory markers with smoking heaviness parameters (exhaled CO, cigarettes/d, and packyears) for all smokers are shown in Table 2 , adjusted for age, sex, race, body mass index, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, diabetes mellitus status, antihypertensive medication use, and lipid medication use. These models indicate strong, independent associations between smoking heaviness markers and the urinary F 2 :Cr ratio, WBC counts, and myeloperoxidase (P<0.001). No statistically significant associations were observed between CRP, D-dimers, and fibrinogen levels and any smoking heaviness marker in the adjusted models. These models were not affected substantively when adjusted by alcohol use or alternative models of adiposity (data not shown).
Inflammatory Markers After Smoking Cessation
Of the 888 participants who made an aided quit attempt and completed the year 1 assessments, 344 (29.7%) participants had biochemically confirmed 7-day point-prevalence abstinence at 1 year. Their characteristics at the year 1 visit are in Table I Table 3 describes unadjusted changes in the inflammatory markers and other variables after 1 year among smokers who made an aided quit attempt. These models were not affected substantively by adjusting for alcohol use or alternative models of adiposity (data not shown). Despite greater weight gain and increases in insulin resistance, abstinence at 1 year-when compared with continued smoking-was associated independently with decreases in the urinary F 2 :Cr ratio (P<0.001) and WBC counts (P<0.001) in models adjusting for the baseline inflammatory marker value, change in weight, and change in homeostasis model of insulin resistance. These results are consistent with the simple correlations described above and continued to be statistically significant (P<0.001) after further adjusting for age, sex, race, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, diabetes mellitus status, antihypertensive medication use, lipid medication use. Results of models evaluating the effects of successful abstinence compared with continued smoking on the inflammatory markers after 1 year among smokers who made an aided quit attempt (n=888) are shown in Table 4 . These models accounted for 24% to 48% of the variance in the inflammatory markers.
Discussion
In this large cohort of contemporary smokers, we observed independent associations between smoking heaviness and three inflammatory markers that are associated with CVD risk-the urinary F 2 :Cr ratio, myeloperoxidase, and WBC count-but not with CRP, fibrinogen or D-dimer. After 1 year, successful abstainers experienced statistically significant, independent reductions in urinary F 2 :Cr ratios and WBC counts, despite weight gain and increased insulin resistance, whereas differences in myeloperoxidase, CRP, D-dimer, and fibrinogen were not observed.
In some population-based studies, active cigarette smoking has been associated with elevated levels of each of the 6 inflammatory markers we investigated [19] [20] [21] [22] [23] [25] [26] [27] ; however, these studies have had conflicting results, especially for the most commonly studied markers, CRP 20, 23 and WBC count. 20, 25 These discrepant findings may have been because of the evolution of the population of smokers, imprecise assessment of smoking status and burden, and changes in laboratory measurement technology over time. The characteristics of smokers have changed since the first population-based studies that found associations between smoking and inflammation >30 years ago. Contemporary smokers are older, weigh more, are less educated, and have more medical and psychiatric comorbidities. 2, 28 They also smoke less but seem to gain more weight after smoking cessation. 2, 28, 29 Our assessment of smoking status (biochemically confirmed 7-day point prevalence abstinence) was state of the art and avoids misclassification bias. Also, bioassays for several of the inflammatory markers have changed over time, yielding differing and presumably, more precise results. The results of this study reflect the relationships between smoking and inflammatory processes in a contemporary sample of smokers using the best contemporary research approaches. Differences in the cross-sectional relationships between smoking heaviness and inflammatory markers and longitudinal changes in these same markers with successful abstinence versus continued smoking may reflect distinct biological processes. For example, CRP is a nonspecific marker of inflammation that in large part reflects adiposity and responses to adipocytokines. 30 In our study and in others, CRP levels seem to be more related to weight and weight gain than changes in smoking heaviness with strong observed associations between CRP levels and measures of adiposity. 20, 31 WBC count is also a nonspecific marker that has consistently been associated with smoking and smoking heaviness, 20, 32 likely reflecting different inflammatory pathways less closely linked to adiposity. The urinary F 2 :Cr ratio primarily reflects oxidant stress because of lipid peroxidation, 21, 33 which promotes atherogenesis. 34 Like WBC count, the urinary F 2 :Cr ratio had strong, independent cross-sectional associations with each marker of smoking heaviness, and levels improved with cessation, suggesting a causal relationship. An association between increased levels of urinary isoprostanes and smoking has been described 27 ; however, to our knowledge, this is the first to prospectively demonstrate its reduction with smoking cessation. Myeloperoxidase also contributes to oxidative damage and has been hypothesized to be a catalyst for low-density lipoprotein oxidation in vivo. 35 Like the urinary F 2 :Cr ratio and WBC, it showed significant cross-sectional associations with each smoking heaviness marker; however, it did not improve with smoking cessation.
Despite a wealth of evidence linking cigarette smoking with CVD, the exact mechanisms that contribute to this association remain unclear. Our findings suggest that smoking increases risk by increasing oxidant stress that improves on successful cessation, despite the weight gain and worsening insulin resistance that are common after smoking cessation. 
Limitations
This was a longitudinal, observational study conducted in the context of a randomized comparative effectiveness trial of smokers highly motivated to quit. Eventual quitters and continuing smokers differed in many factors that may have affected the relationships between the inflammatory markers studies and smoking heaviness markers, so residual confounding cannot be excluded. However, the strong associations, multiple factors we adjusted for, and consistent findings after 1 year, at least for the urinary F 2 :Cr ratio and WBC count, strongly suggest that our findings are accurate and that oxidant stress plays an important role in the inflammatory component of smoking-related CVD risk. As commonly observed in studies of smoking cessation, ≈26% of subjects did not return for their 1-year follow-up visit. This is comparable drop-out rates in other recent clinical trials of smoking cessation pharmacotherapy. 36, 37 We measured CO to ascertain quit status. Some investigators prefer serum cotinine; however, it may also be influenced by environmental exposure such as second-hand smoke. From a tobacco science perspective, the use of CO to verify smoking status is common and in our opinion, is preferable, as does not capture nicotine from nicotine replacement products. Participants from Milwaukee were older, more often were non-white, and had lower socioeconomic status. A sensitivity analysis that adjusted for recruitment site did not reveal any substantive differences in the standardized coefficients or levels statistical significance, for which changes were minimal and at the thousandth decimal point (data not shown). Finally, we cannot exclude the possibility that there may have been differences in undiagnosed infections, inflammatory diseases, or malignancies between continuing smokers and abstainers that may have confounded our findings.
Conclusions
In this large cohort of contemporary smokers, smoking heaviness was associated independently with urinary F 2 :Cr ratio, WBC counts, and myeloperoxidase levels, but not with CRP, D-dimer, or fibrinogen levels. After 1 year, smoking cessation lead to significant reductions in the urinary F 2 :Cr ratio and WBC counts despite weight gain and worse insulin resistance, suggesting that oxidant stress may mediate increased inflammation and CVD risk in smokers.
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